management of mdr-tb transition from hospital …...• development of sop’s, training materials,...
TRANSCRIPT
1
Management of MDR-TB – Transition from hospital based management to community based management in
Bangladesh
Refiloe Matji
TB CARE II Director
October, 2016
USAID TB CARE II PROJECT - BANGLADESH
BACKGROUND
• TB CARE II was a USAID funded project from 2011-2015
• The aim was to support the National TB Program to reduce
morbidity and mortality due to TB
• One of the objectives of the project was to strengthen the
management of MDR TB through early detection, quality
diagnosis and treatment
USAID TB CARE II PROJECT - BANGLADESH
Epidemiology
• High burden of both drug
susceptible and drug resistant
TB
• TB Prevalence: 411/100 000
• TB Incidence: 225/100 000
• 4,700 cases of MDR TB in
2014
• MDR TB prevalence:
1.4% of new cases
28.5% of retreatment cases
USAID TB CARE II PROJECT - BANGLADESH
Key Partners
• Government Counterparts from the National TB Control Program
• TB CARE II team
• Partners in Health
• World Health Organization
• Damien Foundation
• Local NGO’s
USAID TB CARE II PROJECT - BANGLADESH
MDR TB Status
• Long Waiting periods before treatment initiation
• Long hospitalization > 6 months
• Limited initiation sites
• Limited diagnostic sites
• Poor infection control
USAID TB CARE II PROJECT - BANGLADESH
Introduction of Community based MDR TB Management
• Implementation started in 3 sites
• Introduction of Xpert MTB/Rif
• Formation of National PMDT Committees at different levels
• Development of SOP’s, training materials, R&R tools and other
supportive tools
• Increase the number of MDR TB beds
• Psycho-social and nutrition support to patients
• Introduction of m-Health for monitoring and supervision
of treatment
USAID TB CARE II PROJECT - BANGLADESH
TB m-Health
• m-Health was introduced
in November 2013.
• By July 2015, 34 districts
were covered by m-Health.
• Total of 723 health workers
trained
• 1,054 MDR cases
monitored by 418 DR TB
DOT providers monitored
electronically.
USAID TB CARE II PROJECT - BANGLADESH
MDR TB Cases diagnosed and treated
Ca
rry o
ve
r
from
20
08
TB CAR II Start to work with NTP
USAID TB CARE II PROJECT - BANGLADESH
Key Results
Key Results
• Rapid transfer of patients to community
increased yearly treatment enrollment
from 390 in 2011 to approximately 1,200
in 2014.
• 2,620 patients enrolled into MDR-TB
treatment between 2012 and June 2015.
• Treatment initiation delay after
diagnosis reduced from > than two
months to < than a week.
• Analysis of project data showed a
treatment completion of 84%
• 2,956 household contacts screened; 91
TB and 26 RIF cases identified
USAID TB CARE II PROJECT - BANGLADESH
Analysis on treatment initiation time in selected
sites
158
15 15 12
2011 2012 2013 2014
NIDCH
Median # of Days
84
33
7 3
2011 2012 2013 2014
Chittagong CDH
Median # of Days
69
1511
6
2011 2012 2013 2014
National
Median # of Days
USAID TB CARE II PROJECT - BANGLADESH
Key componentsTraining
Quality
clinical care
Counseling
Daily Rx supervision
at home level
Regular Monitoring
& SupervisionCash
transfer
USAID TB CARE II PROJECT - BANGLADESH
Conclusion
• The community based management of MDR-TB
showed a great potential for Bangladesh to increase
access to and quality of MDR-TB services. The
results suggests that a high cure rate with minimal
treatment interruption and failure is achievable.
USAID TB CARE II PROJECT - BANGLADESH
Acknowledgments
• National TB Control Program (Bangladesh)
• Partners in Health team (Michael Rich et al)
• WHO team
• Local NGO’s
• Patients
USAID TB CARE II PROJECT - BANGLADESH
THANK YOU
USAID TB CARE II PROJECT - BANGLADESH
TB CARE II, is funded by United States Agency for
International Development (USAID) under Cooperative
Agreement Number AID-OAA-A-10-00021. The project team
includes prime recipient, University Research Co., LLC (URC),
and sub-recipient organizations Jhpiego, Partners in Health,
Project HOPE along with the Canadian Lung Association;
Clinical and Laboratory Standards Institute; Dartmouth
Medical School: The Section of Infectious Disease and
International Health; Euro Health Group; and The New Jersey
Medical School Global Tuberculosis Institute